Post-ASCO 2024 Lung Cancer Highlights

Interactive webinar featuring presentations & discussions on selected abstracts from ASCO 2024
Chair: Professor Sanjay Popat | Moderator: Dr Melissa Johnson
19 June | 10:00–11:30 CDT/ 16:00–17:30 BST/ 17:00–18:30 CEST

This webinar is for HCPs and allied health professionals only. Please apply for registration and we’ll confirm your application once received.

Agenda

Timings are in CDT

10:00–10:10 | Session 1: Latest in consolidative therapy and palliative care

• NRG-LU002: Randomized phase II/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC) – #8506: Puneeth Iyengar
• Comparative effectiveness trial of early palliative care delivered via telehealth versus in person among patients with advanced lung cancer – #LBA3: Joseph Greer

10:10–10:20 | Session 2: Advances in resectable lung cancer

• Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816 – #LBA8010: Nicolas Girard
• Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFRmutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC) – #8005: Tom John

10:20–10:40 | Panel discussion

10:40–10:50 | Session 3: Updates in EGFR mutated lung cancer EGFR-targeted therapies

• Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study – #LBA4: Terufumi Kato
• Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial – #LBA8505: Natasha Leighl

10:50–11:00 | Session 4: Advances with targeted therapies

• Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study – #LBA8500: Luis Paz-Ares
• BEAT-meso: A randomized phase III study of bevacizumab (B) and standard chemotherapy (C) with or without atezolizumab (A), as first-line treatment (TX) for advanced pleural mesothelioma (PM)—Results from the ETOP 13-18 trial – #LBA8002: Sanjay Popat

11:00–11:25 | Panel discussion

11:25–11:30 | Closing remarks & end of webinar

This webinar is for HCPs and allied health professionals only. Please apply for registration and we’ll confirm your application once received.